MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE

Abstract: multi-specific binding proteins that bind to and kill human cancer cells expressing cd33 (siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cd33 expressing cancer. the invention relates to multi-specific binding proteins that bind to human cancer cells expressing cd33, and exhibit high potency and maximum lysis of target cells compared to anti-cd33 monoclonal antibodies.

Inventor(s): Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Dhruv Kam Sethi, William Haney, Bianka Prinz, Bradley M. Lunde, Ronnie Wei, Daniel Fallon, Steven O'Neil

CPC Classification: C07K16/283 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154261